Clinical-stage biopharmaceutical company developing immuno-oncology therapies.
Arcus Biosciences, Inc. is a prominent clinical-stage biopharmaceutical firm focused on pioneering cancer therapies within the United States. Established in 2015, Arcus Biosciences develops and commercializes a diverse pipeline of innovative treatments aimed at addressing critical unmet needs in oncology. Central to its portfolio are several promising candidates currently advancing through clinical trials.
Among its leading investigational therapies is Etrumadenant, a Phase 1b/2 dual A2a/A2b adenosine receptor antagonist designed to modulate the tumor microenvironment. Additionally, Zimberelimab, an anti-PD-1 antibody, is progressing through a Phase 1b trial as a monotherapy, showcasing potential in immune checkpoint inhibition strategies.
Arcus Biosciences is also actively developing Domvanalimab, an anti-TIGIT monoclonal antibody in Phase 2 development. This therapy is being studied in combination with Zimberelimab for first-line treatment of metastatic non-small cell lung cancer, highlighting the company's commitment to innovative combination therapies. Moreover, Quemliclustat, a Phase 1/1b small-molecule CD73 inhibitor, and AB521, an oral HIF-2a inhibitor in Phase 1, further underscore Arcus Biosciences' dedication to advancing novel approaches against challenging cancers such as metastatic pancreatic cancer and von Hippel-Lindau disease.
Strategic collaborations bolster Arcus Biosciences robust research and development efforts. These include partnerships with AstraZeneca and BVF Partners L.P., aiming to evaluate Domvanalimab in combination with Imfinzi in Phase 3 trials. Additionally, the company has formed key alliances with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to advance innovative treatments like anti-CD39 antibodies, illustrating its collaborative approach to expanding therapeutic options for cancer patients worldwide. Headquartered in Hayward, California, Arcus Biosciences, Inc. remains at the forefront of advancing transformative oncology treatments through rigorous scientific innovation and strategic partnerships.